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ABSTRACT
Introduction: Classification TNM 1997 defines renal cell carcinoma smaller than 7 cm and
confined to the kidney as stage T1. Our goal is to discuss if tumors smaller than 4 cm have the same
behavior characteristics then tumors between 4 and 7 cm, to compose the same stage of the disease.
Materials and Methods: Retrospective assessment of 138 patients in stage T1 (TNM - 97),
divided into 2 groups; group-1: composed of 65 patients (47%) with tumors < 4 cm, and group-2:
composed of 73 patients (53%) with tumors between 4 and 7 cm. The following prognostic factors
were assessed in the recurrence of the disease and survival of patients: nuclear degree, microvascular
invasion, sarcomatous degeneration, and involved lymph nodes. Statistical evaluation has been
accomplished through the log rank test, chi-square test, and Fisher’s exact text.
Results: Average tumor size was 2.5 cm for group-1, and 5.3 cm for group-2. In group-2,
there was the predominance of worse prognostic factors, with high-grade tumors (p = 0.01) and
presence of microvascular invasion (p = 0.001). Sarcomatous tumors and involvement of lymph
nodes did only happen in group-2. Disease-free survival for group-1, analyzed in the median period
of 36 months, was 100%, and for group 2, in the median period of 31 months, was 81% (p = 0.008).
Conclusion: The results obtained allow the conclusion that the present stage T1 for renal
cell carcinoma gathers tumors of different evolution, being therefore recommendable the stratification
in T1a for tumors smaller than 4 cm, and T1b for tumors between 4 and 7 cm.
Key words:  kidney; carcinoma, renal cell; neoplasm staging; prognosis; classification; survival
Int Braz J Urol.  2003;  29: 106-12
International Braz J Urol
Official Journal of the Brazilian Society of Urology
Vol. 29 (2): 106-112, March - April, 2003
INTRODUCTION
Renal cell carcinoma (RCC) is the third most
common neoplasia of urinary tract. In last decades,
with increased sensibility of imaging methods, the
early diagnosis of this neoplasia has become more
frequent, reaching up to 60% in the incidental form
(1).
Due to the increase in the incidence of renal
tumors, the urologist should be familiarized with the
characteristics of this tumor, as well, as its evolution.
One of the first staging systems used was the one of
Robson et al. (2), but the stage TNM presents a more
detailed anatomic classification, and its use offers a
common language for the treatment and prognostic
evaluation of patients having RCC. Stage TNM was
last modified in 1997 (3), nevertheless, there are pro-
posals for a new modification (4-8).
We have retrospectively assessed 2 groups
of patients, by comparing the group having tumors
smaller than 4 cm with the group having tumors be-
tween 4 and 7 cm, analyzing the differences of prog-
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Table 1 – Characteristics of tumors.
  N (%) High-Grade (%)       Microvascular          Sarcomatous (%)         Positive            Size  (cm)
           Invasion (%)                                                   Lymph nodes (%)
Group 1  65 (47)        11 (17)                  2 (3)                    0                0     2.5 + 0.7
 < 4 cm
Group 2  73 (53)       47 (64)             17 (23)               4 (5.5)            2 (1.4)     5.3 + 1.0
 4 - 7 cm
nostic factors for the recurrence of disease and sur-
vival of patients.
MATERIALS AND METHODS
In the period between January 1988 and July
2002, 138 patients bearing RCC stage T1 (TNM -
97), were operated by the same group of surgeons in
2 hospitals and were retrospectively assessed. Pre-
surgical evaluation included ultrasonography, com-
puter tomography of abdomen and/or magnetic reso-
nance imaging and chest x-ray. Post-surgical follow
up varied between 2 and 138 months (median = 33
months). Patients were asked about their participa-
tion in the study through post-informed consent, and
afterwards, a retrospective analysis through patients’
records data was accomplished. Clinical information
collected included age, sex, side of tumoral kidney;
time of diagnosis, surgical treatment (radical or con-
servative), pathologic examination, and post-surgical
follow up. All pathologic material (slides and frag-
ments embedded in paraffin) was revised in the light
microscope by just one pathologist, being checked
the tumoral diameter, cellular type, nuclear degree,
presence of microvascular intra-tumoral invasion, and
positive lymph nodes. In post-surgical follow up, the
following examinations were accomplished: chest x-
ray, abdominal ultrasonography and/or computer to-
mography (interspersed) and hematological exami-
nations at each 3 months during first year, every six
months from second to fifth year, and annually after
this period.
To assess the impact of tumoral diameter with
factors of worse prognosis in the recurrence of the
disease and survival of patients, they have been di-
vided into 2 groups: a) group-1: tumors smaller than
4 cm; b) group-2: tumors between 4 and 7 cm.
Statistical analysis used was the log rank test
for survival curves, chi-square test, and Fisher ex-
act test to assess the difference between the 2 groups.
P < 0.05 was considered statistically significant.
RESULTS
For the total of 138 patients, 103 men (75%)
and 35 women (25%), the tumor was in the right kid-
ney in 71 patients (51%), in the left in 66 patients (48%),
and in both in one patient (1%). For group-1, the sur-
gery was conservative in 28 (37%) cases, and radical
in 37 (63%), and in group-2, it was conservative in 8
cases (11%) and radical in 65 (89%). Table-1 repre-
sents the tumoral characteristics in the 2 groups.
Groups of Patients According to Tumoral
Diameter
Group-1 included the total of 65 patients
(47%), with mean age of 59.2 years (38 to 76 years);
follow up varied from 2 to 138 months (median = 36
months), and the mean size of the tumor  was 2.5 ±
0.7 cm. Group-2 was composed of 73 patients (53%),
with mean age of 57.9 years (9 to 87 years); follow
up varied from 2 to 111 months (median = 31 months),
and the mean size of the tumor was 5.3 ± 1.0 cm.
Tumor Characteristics
In group-1, 11 patients (17%) presented high-
grade tumors (III and IV), and in group-2, 47 patients
(64%) presented high-grade tumors (p = 0.01); 2 pa-
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tients of group-1 (3%) presented microvascular inva-
sion, while 17 (23%) patients in group-2 presented
microvascular invasion (p = 0.001). Lymph nodes in-
volvement occurred in 2 patients (1.4 %) from group-
2, not occurring in any patient of group-1 (p = 0.1).
Cell Types
There was homogeneous distribution in re-
lation to cellular types. Clear cell tumor was the pre-
dominant in both groups, and sarcomatous degenera-
tion was present only in group-2, in 4 patients (5.5%)
(p = 0.05).
Recurrence of Disease
In group-1, there was no tumoral recurrence.
In group-2, it happened in 8 of 73 patients (11%), 15
months after surgery in average (5 to 45 months).
Survival
From the 8 patients with recurrence, 4 ended
in obit during follow up (Table-2). The disease-free
survival curve was of 100% and 81% (p = 0.008) for
groups-1 and 2, respectively (Figure-1). There was
no loss in follow up for any patient.
DISCUSSION
This work has demonstrated that RCC smaller
than 4 cm are in their majority low-grade tumors,
rarely present microvascular invasion, do not present
sarcomatous degeneration, nor involved lymph nodes,
having probability of survival equivalent to 100% in
3 years.
The behavior of small volume renal tumors
remains unknown (9), but tumoral size is related to
malignant potential (10). The size of neoplasia as
prognostic factor for localized tumors is generating
controversy (8). The incidence of tumors with less
than 4 cm, from 28% in 1985 increased to 61% in
1995 (9), as well as the number of renal conserva-
tive surgeries increased, what therefore makes rel-
evant the study of biological behavior of this sub-
group, which includes RCC with less than 7 cm.
Targonski et al. (7), studied 93 individuals with RCC,
and concluded that patients with tumors smaller than
5 cm presented greater survival. In another study, a
more favorable evolution has been observed in pa-
tients with tumors smaller than 5.5 cm (9). Lee et
al. (10), analyzing 252 renal tumors smaller than 4
cm, observed a high incidence of multimodality  and
metastasis in tumors from 2.1 to 4 cm, contra-indi-
cating conservative surgery for tumors greater then
2 cm. This result is contrary to the majority of works
on conservative surgery for RCC, in which lesions
smaller than 4 cm treated with partial or radical sur-
gery presented similar evolution (4,5,9). Other con-
troversial work was accomplished by Belldegrun et
al. (11), which declares that patients treated with
conservative and radical surgery present similar evo-
Table 2 – Demographic data for the 8 recurrences in group-2.
Sex Age         Tumoral Grade      Microvascular  Cellular                  Positive          Evolution
  Size (cm)                                       Invasion                     Type                     Lymph nodes
M 61        4  high         + sarcomatoso          - óbito
F 65        5  low          -    papilar         + óbito
M 56        5,5  high         + sarcomatoso          - óbito
M 75        5,5  high          -    papilar          - CED
M 54        6  high         +    papilar         + CED
M 46        7  high         +  cel. claras          - CED
M 51        7  high          -  cel. claras          - óbito
M 60        7  low          -  cel. claras          - CED
WED = With Evidence of Disease
sarcomatous
papil y
sarcomatous
papill y
papill y
lear cell
lear cell
lear cell
death
death
death
WED
WED
WED
death
WED
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Figure 1 - Disease-free survival curves (p = 0.008).
lution, with tumors smaller than 4 cm, as wells as be-
tween 4 and 7 cm.
RCC staging is one of the most important prog-
nostic factors (12,13), being a crucial point in the de-
termination of therapeutic approach. With the objec-
tive of universalizing the TNM classification for RCC,
there have been several changes already, being it pres-
ently in the fifth edition (3). Due to the fact of believ-
ing that the behavior of stage T1 is not completely know,
(14) various proposals aroused as cutting point for stage
T1: 4 cm (4,5), 4.5 cm (6), 5 cm (7) and 5.5 cm (8),
justifying the subdivision of clinical stage T1 for a bet-
ter selection of patients for conservative surgery. On
the other hand, maintenance of current TNM is also
defended (15,16). Results obtained in 1997 (17) and
others, more recent (4,5), propose the modification of
current TMN classification to T1a for tumors smaller
than 4 cm, and T1b for tumors between 4 and 7 cm,
what would allow for a better prediction of specific and
disease free cancer survival, thus optimizing the prog-
nostic (4). Based in previous studies, we share the
opinion that tumors smaller than 4 cm are less ag-
gressive.
It is attributed to high-grade tumors a 5
years survival of 46% (18), but the presence of
intratumoral microvascular invasion gives chance
of disease progression in half of the cases (19). In
our case, high nuclear degree and microvascular
invasion were predominant in group-2, having sta-
tistical significance when compared to the group
of patients having tumors smaller than 4 cm (group-
1). Another data that is very important is that posi-
tive lymph nodes and sarcomatous pattern has only
happened in group-2. It is well known that sarco-
matous degeneration gives mean survival of 49
months for tumors smaller than 7 cm confined to
the kidney, while lymph node invasion results in a
5 years survival equivalent to 33% (18).
Specific cancer survival for patients with
stage T1 tumors in 10 years varies from 86% to
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92%. Nevertheless, when current T1 is subdivided
into tumors smaller than 4 cm, survival in 10 years
varies from 97% to 99%; but for tumors between 4
and 7 cm, survival was between 76% and 84% (4).
Our work has shown survival free of disease of 100%
for group-1, and 81% for group-2, showing a clear
correlation between  tumor size, disease recurrence,
and deaths for tumors greater than 4 cm. Survival of
patients with disease recurrence is of 3 years, in spite
of immunotherapy (20).
Therefore, we believe that the subdivision
into T1a and T1b, with cutting point of 4 cm, is needed
for perfecting the current TNM system, for it creates
a more homogeneous group, practically without worse
prognostic factors. Our results suggest that tumors
greater than 4 cm are potentially more aggressive than
smaller tumors, and are not supposed to be in the same
stage of disease.
As a future perspective, we believe that this
series will confirm the international studies defend-
ing the subdivision of present clinic stage T1 (TNM -
1997).
CONCLUSION
Current RCC classification, stage T1, in-
cludes tumors of different evolution, being recom-
mendable the stratification into T1a and T1b with a
cut level of 4 cm, in order to homogenize the groups
and have a better correlation with prognosis.
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EDITORIAL COMMENT
The factors that are most important for stag-
ing renal cell carcinoma (RCC) are the tumoral size
and the existence of metastasis in lymph nodes. For
the kidney, as well as for the urinary bladder, mi-
crovascular invasion should occur, but it does not
change the stage, differently to what happens with
the testicle.
Partial nephrectomy, currently, has been the
preferable treatment of these tumors. Tumor size and
location are limiting factors for the procedure. With
the introduction of laparoscopic nephrectomy, these
aspects became even more important.
Subdivision of stage T1 in T1a and T1b (< 4
cm and 4 to 7 cm) is very important for surgical suc-
cess and tumor recurrence.
Presently, it is well determined that the sur-
gical margin is an important factor, but there is no
consensus on the thickness of this margin. The litera-
ture refers it as 0.5 cm at least, 0.5 to 1.5 cm, 1 cm,
1.5 cm, and a region of macroscopically normal renal
tissue (1).
The high-grade of the tumor, as well as sar-
comatous degeneration are important factors for
worse prognosis. In the present work, there was not
any case of sarcomatous type in group-1 (tumors
smaller than 4 cm).
Fuhrman nuclear grading (FNG) (2) is corre-
lated to TNM staging in relation to the progression of
neoplasia, i.e., as FNG increases, greater are the chances
of progression. On the other hand, the thickness of sur-
gical resection margin did not show correlation with
tumoral progression (1). The grading of nuclear alter-
ations of Fuhrman (FNG) is probably the most used
parameter as indicator of tumoral prognosis (3).
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In this way, the association of worse progno-
sis factors like FNG with RCC greater than 4 cm,
strengthens the recommendation of subdividing the
TNM classification into T1a and T1b for renal carci-
noma.
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EDITORIAL COMMENT
In the present article, doctor Dall’Oglio and
co-workers found that renal cell carcinomas with
less than 4 cm in diameter are in general low-grade
tumors, do not present microvascular invasion, do
not present sarcomatous differentiation and do not
involve lymph nodes, presenting a survival
probability of 100% in 3 years, different from those
tumors between 4 and 7 cm in diameter. Therefore,
this is a very much timely and welcome publication
because it is one more validation of the very recent
2002 TNM staging modification of renal tumors on
which the pT1 stage was substratified in pT1a
(tumors less than 4 cm) and pT1b (tumors from 4 to
7 cm).
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